SCHEMBL7179656

SCHEMBL7179656

COc1cccc(Cl)c1C(=O)Pc1c(Oc2ccccc2)cc(Oc2ccccc2)cc1Oc1ccccc1.[LiH]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
KMT2A Q03164 3/20 0.40
PNLIP P16233 1/20 0.40
FABP4 P15090 1/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HTT P42858 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.38
THRB P10828 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
DPP4 P27487 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182633 0.93 TTR (0.45) TTRCA12CA1CA2CA7
SCHEMBL7187892 0.93 KMT2A (0.42) KMT2AFABP4MEN1LMNAL3MBTL1
SCHEMBL7184706 0.88 KMT2A (0.39) KMT2APNLIPFABP4MEN1LMNA
SCHEMBL7189149 0.86 KMT2A (0.41) TTRCA12CA1CA2CA7
SCHEMBL7175847 0.85 TTR (0.45) TTRKMT2AMEN1ALDH1A1MAPT
SCHEMBL7183739 0.85 MAPT (0.44) CA12CA1CA2CA7CA9
SCHEMBL7190107 0.84 CA12 (0.43) TTRCA12CA1CA2CA7
Lithium SCHEMBL7189155 0.84 KMT2A (0.41) TTRCA12CA1CA2CA7
SCHEMBL7185394 0.82 ABCG2 (0.44) KMT2AMEN1LMNAMAPTRAB9A
SCHEMBL7182614 0.81 MEN1 (0.43) TTRKMT2AMEN1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 TTR 2781/4885CA12 1552/4885CA1 2219/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 TTR 2797/4885CA12 1320/4885CA1 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.